Anika Appoints Stephen Goldy as Vice President of U.S. Sales
April 30 2019 - 4:05PM
Business Wire
Seasoned commercial leader to oversee hybrid
commercial organization and upcoming launch of Bone Repair Surgical
Therapy in the U.S.
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedic and regenerative medicines company specializing in
therapeutics based on its proprietary hyaluronic acid ("HA")
technology, today announced the appointment of Stephen Goldy to the
newly created position of Vice President of U.S. Sales. Mr. Goldy
brings over 20 years of experience developing and implementing
sales strategy, with a specialization in the orthopedic, sports
medicine and general surgery markets. In this new role, Mr. Goldy
will oversee sales strategy and operations for the Company’s hybrid
commercial organization in the United States.
“Stephen is an important addition to our team as we establish
and execute our new hybrid commercial organization in the U.S.,”
said Joseph Darling, President and Chief Executive Officer of Anika
Therapeutics. “Stephen brings more than two decades of sales
experience and a deep understanding of the orthopedic surgery and
sports medicine markets, which will be critical to our near- and
long-term growth. We look forward to benefitting from his knowledge
and expertise as we prepare for the launch of our first
surgically-delivered regenerative therapy for bone repair
procedures in the U.S. in the second half of this year. His proven
track record of defining and exceeding sales targets and
cultivating and managing national accounts will be invaluable as we
transform Anika into a global commercial company.”
“I am very excited to join Anika at this transformational time
in its evolution and look forward to developing and implementing
its hybrid commercial model in advance of the upcoming launch of
the Company’s bone repair product in the U.S.,” said Stephen Goldy,
Vice President of U.S. Sales at Anika Therapeutics. “Anika’s deep
orthopedic and regenerative medicine pipeline and solid reputation
for high-quality, innovative treatments positions the company for
its next phase of growth.”
Prior to joining Anika, Mr. Goldy spent seven years at ConMed
Orthopedics, a global medical device manufacturer, as Regional Vice
President and Director of Sales. Before joining ConMed, Mr. Goldy
served as National Accounts Manager for Creekridge Capital, a
privately-held equipment leasing company, and Global Financial
Services Manager at Smith and Nephew. Mr. Goldy holds a Master of
Business Administration and Bachelor of Science from the University
of Massachusetts.
About Anika Therapeutics, Inc.Anika Therapeutics,
Inc. (NASDAQ: ANIK) is a global, integrated orthopedic and
regenerative medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of
patients with degenerative orthopedic diseases and traumatic
conditions with clinically meaningful therapies along the continuum
of care, from palliative pain management to regenerative tissue
repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
and CINGAL®, which alleviate pain and restore
joint function by replenishing depleted HA,
and HYALOFAST, a solid HA-based scaffold to aid
cartilage repair and regeneration. For more information about
Anika, please visit www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190430006019/en/
For Investor Inquiries:Anika Therapeutics, Inc.Sylvia Cheung,
781-457-9000Chief Financial Officer
For Media Inquiries:W2O GroupSonal Vasudev,
917-523-1418sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Sep 2023 to Sep 2024